Cost-effectiveness analysis of malaria rapid diagnostic test in the elimination setting

Yanqiu Du  
Fudan University School of Public Health  
https://orcid.org/0000-0003-2200-0477

Xiaoxiao Ling  
University College London

Jiajie Jin  
Fudan University

Huayun Zhou  
Jiangsu Institute of Parasitic Diseases

Si Zhu  
Fudan University School of Public Health

Guoding Zhu  
Jiangsu Institute of Parasitic Diseases

Wei Wang  
Fudan University School of Public Health

Jun Cao  
Jiangsu Institute of Parasitic Diseases

Jiyan Huang  
Jiyanhuang@fudan.edu.cn  
https://orcid.org/0000-0003-4166-6119

Research Article

Keywords: Cost-effectiveness analysis, Monte Carlo simulation, Malaria elimination, Rapid diagnostic test, Microscopy

DOI: https://doi.org/10.21203/rs.3.rs-28733/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: As more and more countries approaching the goal of malaria elimination, malaria rapid diagnostic tests (RDT) was recomended to be a diagnostic strategy to achieve and maintain the statute of malaria free, as it's less requirments on equipment and expertise than microscopic examination. But there are very few economic evaluations to confirm whether RDT was cost-effective in the setting of malaria elimination. This research aimed to offer evidence for helping decision making on malaria diagnosis strategy.

Methods: A cost-effectiveness analysis was conducted to compare RDT with microscopy examination for malaria diagnosis, by using a decision tree model. There were three strategies of malaria diagnostic testing evaluated in the model, 1) microscopy, 2) RDT, 3) RDT followed by microscopy. The effect indicator was defined as the number of malaria cases treated appropriately. Based on the joint perspective of health sector and patient, costs data were collected from hospital information systems, key informant interviews, and patient surveys. Data collection was conducted in Jiangsu from September 2018 to January 2019. Epidemiological data were obtained from local malaria surveillance reports. A hypothetical cohort of 300 000 febrile patients were simulated to calculate the total cost and effect of each strategy. One-way, two-way, and probabilistic sensitivity analysis were performed to test the robustness of the result.

Results: The results showed that RDT strategy was the most effective (245 cases) but also the most costly (United States Dollar [USD] 4.47 million) compared to using microscopy alone (238 cases, USD 3.63 million), and RDT followed by microscopy (221 cases, USD 2.75 million). There was no strategy dominated. One-way sensitivity analysis reflected that the result was sensitive to the change in labor cost and two-way sensitivity analysis indicated that the result was not sensitive to the proportion of falciparum malaria. The result of Monte Carlo simulation showed that RDT strategy had higher effects and higher cost than other strategies with a high probability.

Conclusions: Compared to microscopy and RDT followed by microscopy, RDT strategy had higher effects and higher cost in the setting of malaria elimination.

Background

Malaria is a parasitic disease caused by Plasmodium spp, which is transmitted to human through the bites of infected anopheline mosquitoes. Although the malaria incidence rate declined globally from 71 to 57 cases per 1000 population at risk between 2010 and 2018 [1]. The global decrease trend appeared to slow from 2014 to 2018 [2]. China continued to make progress on elimination, and reported zero indigenous case since 2017. But here were still about 2500 imported cases [1, 3], and falciparum malaria accounted for more than 85% of them [4].

Malaria diagnostic tests (MDT), such as microscopy (microscopic examination of Giemsa-stained thick and thin blood films) and rapid diagnostic tests (RDT), are now recommended as routine diagnostic
methods by the World Health Organization (WHO) in all suspected malaria patients before treatment [5]. Microscopy, as the conventional laboratory method for malaria diagnosis, needs to be conducted by microscopists with adequate training and essential equipment will also be required. It allows the differentiations of species and stages and the quantification of parasites. However, microscopy examination can have a high proportion of false negatives due to the difficult of maintaining the skill of microscopist, especially in the low transmission areas. RDT uses antibodies to detect one or several parasite-specific antigens in a drop of fresh blood. They do not require any special equipment. Therefore, RDT is suitable for primary health care institutions with limited facilities and unskilled staff. However, they may also fail to accurately diagnose for cases with low parasitaemia, and false positives are possible due to cross reactions [6-9].

Globally, it has been estimated that 276 million RDTs for malaria were sold in 2017, and the number rose to 412 million in 2018 [1]. RDT is being used more and more, regardless of the transmission setting. In sub-Saharan Africa, RDT has now become the most widely-used method for malaria diagnosis among suspected patients in public healthcare institutions [2]. However, previous economic evaluations of RDT were mainly performed in Africa, there was very little evidence from the elimination setting [10]. Moreover, many factors that impact the result of a cost-effectiveness analysis (CEA), such as incidence rate, the distribution of Plasmodium species, labor cost, and health workers' awareness of malaria, were very different in different areas [11, 12]. And previous cost-effectiveness researches barely paid the attention to evaluating the cost of FP case [13-16].

Recent year, more and more countries set elimination as the goal of national malaria program, and many of them with zero indigenous case reported, such as Malaysia, China, Iran, El Salvador [1], it is urgent to know whether RDT is still cost-effective compared to microscopy in malaria elimination setting, and how the cost of FP cases affects the result of cost-effectiveness analysis. For filling these evidence gap, this study conducted a cost-effectiveness of the malaria diagnostic strategies from the joint perspective of health sector and patient, with the real-world data from China in 2018 based on a decision analytical model.

**Methods**

**Study site**

Jiangsu Province is a coastal area in East China. The malaria incidence rate there was about 250 cases per 1000 population at risk in the 1960s [17]. After decades-long efforts, there has been no indigenous case in Jiangsu since 2011. However, imported Plasmodium infections in this area have been increasing with the development of international trade, which poses tremendous threat for elimination [18-20]. In 2018, there were 243 imported malaria cases reported, which increased by 1.67% compared to 2017 (239 cases). All of them were adults, and the majority were male migrant workers who had been returned from sub-Saharan Africa with P. falciparum infections [19].

**Diagnostic strategies**
Three strategies of malaria diagnostic testing (MDT) were compared in the model. Three types of febrile patients whose body temperature exceeded 38.5 degrees celsius would be involved in the malaria diagnostic testing, including 1) malaria case diagnosed according to clinical symptoms, 2) suspected malaria cases, 3) patients with unexplained fever. In the first strategy (MDT1), these febrile patients would undergo microscopy test, and patients with a positive result would be diagnosed as malaria. In the second strategy (MDT2), RDT were used, and diagnosis would be made based on the test results. In the last strategy (MDT3), patients would be tested using RDT at first, and those with a positive result would be followed by microscopy examination. If the results of microscopy were still positive, they would be confirmed as malaria.

**Decision-analytic model**

To compare the three malaria diagnosis strategies, a decision tree model was developed using TreeAge Pro software (Version 2019 - R1.1, TreeAge Software, LLC, Williamstown, United States). Figure 1 presents the basic structure of the decision tree. A hypothetical cohort of 300,000 febrile patients were simulated which is approximately the annual number of febrile patients who need blood tests in Jiangsu. Patients could either have malaria or not. The number of malaria cases was determined by the prevalence of malaria among febrile patients. Patients with malaria and positive diagnosis test results were considered as true positives. Treatment for different malaria status (uncomplicated and severe malaria cases) was assumed to be implemented according to the national malaria treatment guidelines. Specifically, uncomplicated malaria patients caused by *P. falciparum* would receive artemisinin-based combination therapies (ACTs) such as dihydroartemisinic and piperaquine; uncomplicated malaria patients caused by non-*P. falciparum* would receive chloroquine alone, or with primaquine (for vivax and ovale malaria); and all severe malaria patients would receive artemisinin injection such as artesunate. A part of uncomplicated malaria patients would be treated as inpatient, but all severe malaria patients would be treated as inpatient.

**Measurement of effect**

Considering that the early detection of malaria cases in areas approaching elimination had a high priority, the effect of the MDT strategies was measured by the number of appropriately diagnosed malaria cases (true-positives, TP) in this study. The terminal nodes marked by TP in the decision tree (Figure 1) were considered as the effect defined by this study.

**Measurement of cost**

Costs in a year (2018) were measured from the health institution and patient joint perspective. Since all costs occurred within one year, they were not discounted. Costs were presented in Chinese Yuan (CNY) but then converted to US dollar (USD). And this study used 2018 yearly average currency exchange rate: CNY 6.6174 = USD 1.
Direct costs were categorized as direct medical costs and direct non-medical costs. The direct medical costs included the costs of malaria diagnosis testing (RDT or microscopy), the costs of antimalarial drugs, and other medical costs. The direct non-medical costs were the travel costs for the patients.

The costs of malaria diagnosis included material costs and labor costs of laboratory personnel while the costs of antimalarial drugs differed according to the type of plasmodium and the severity of patient's symptoms.

The costs for false-positive (FP) and false-negative (FN) patients were taken into account according to clinical treatment. FP and FN patients have the same costs (i.e., the costs of malaria diagnosis tests, and antimalarial drugs) compared to those true-positives (TP) or true-negatives (TN) as they shared the same clinical pathways in the decision tree. But a FN patient in one strategy would incur an additional cost, the value of which is equivalent to all medical cost of one severe malaria case in the same strategy, including the cost of diagnosis, antimalarial drugs, and other treatments.

Other medical costs included registration costs, supplementary drug costs (eg, anti-fever medicines, Chinese patent medicines), biochemical diagnosis costs (except the malaria diagnosis test), bedside care costs (only for inpatient).

**Data source**

Costs data from multiple sources were used, such as key informant interviews, hospital information systems (HIS), and patient surveys. The costs for the antimalarial drugs and RDT were made based on key informant interviews with healthcare administrators. According to the national health policy in China, both antimalarial drugs and RDT were purchased and distributed to healthcare facilities by health administrative department, and they were all free for patients. So, the key informant interviews with experts were conducted to estimate their costs. And microscopy test had been kept at extremely low price for patients due to government subsidies. Its costs was also estimated using key informant interviews.

Inpatient costs were estimated based on the data of 25 latest malaria cases in 2018 identified through the HIS of a designated hospital for malaria treatment in Jiangsu province. Outpatient costs were collected from confirmed malaria cases reported between the first week and the forty-ninth week of 2018 via telephone surveys conduceted by one researcher. Each phone number was contacted no more than three times. Cost information was used only if the patient answered the call and gave consent to participate. Transportation costs were also collected by telephone surveys.

Epidemiological data were obtained from malaria surveillance reports, such as the proportion of falciparum malaria, and the proportion of hospitalization for uncomplicated malaria cases. The accuracy of MDT was derived from published literature [21-25].

**Cost-effectiveness analysis and sensitivity analysis**
In deterministic cost-effectiveness analysis, total costs of the cohort were calculated separately for each strategy. Incremental cost-effectiveness ratio (ICER) compared the incremental costs that one strategy would incur over another for one additional malaria case that have been appropriately diagnosed and treated.

To examine the uncertainty brought by the underlying assumptions, a series of one-way sensitivity analyses, including all parameters, were conducted [26]. Moreover, a two-way sensitivity analysis based on the table of value sets in TreeAge software was undertaken to reveal the impact of different proportion of falciparum malaria among all malaria cases. This method was different with normal two-way sensitivity analysis (two variables change in the same direction). The parameter sets in this research would keep the total incidence of malaria fixed while the proportion of falciparum malaria changed from 50% to 100%. That meant when the incidence of falciparum malaria increased, the incidence of non-falciparum malaria decreased by the same value. This range include all fluctuations in the proportion of imported malaria species in China in the past decade [3].

In order to reflect the real situation, total costs and effects for each strategy were estimated by Monte Carlo simulation, a probabilistic sensitivity analysis (PSA) method. Monte Carlo simulation was conducted to incorporate uncertainties of multiple parameters into an analysis by assigning statistical distributions to all relevant parameters. The distributions were assigned to parameters considering the data uncertainty caused by statistical methods and the forecast of cost fluctuations [27]. Beta distribution was assigned to the sensitivity of RDT to make sure it could be constrained between zero and one [26, 28]. Triangular distribution was used for the sensitivity of microscopy, as it was not likely to follow a normal or beta distribution. Gamma distribution was specified for selected cost parameters to capture their strictly-positive and right-skewed nature [16, 28]. Uniform distribution was also used to costs parameters according to the intervals estimated by the key informants [16]. Monte Carlo simulation would generate random draws from these distributions and run 1000 iterations. Uncertainty would be presented in a figure of incremental cost-effectiveness plane.

**Results**

In terms of diagnosis cost, this research found that the average cost of diagnosis by RDT was USD 2.19 per test, including material cost (USD 1.51) and labor cost (USD 0.68). The average cost of diagnosis by microscopy was USD 6.98 per test, including material cost (USD 0.18) and labor cost (USD 6.80, Table 1). In terms of treatment cost, the average cost of oral medication for malaria outpatient was USD 6.04 (chloroquine and primaquine) or 4.53 (dihydroartemisinic and piperaquine). The average cost of artesunate injection for malaria inpatient was USD 132.98. In addition to the cost of malaria diagnosis and antimalaria treatment, other medical costs incurred by outpatient was USD 31.58, mainly including registration and other diagnostic test. Other medical costs incurred by inpatient with uncomplicated malaria was USD 1167.83, mainly including supplementary medication and bedside care. Other medical costs incurred by inpatient with severe malaria was USD 17,569.29, mainly including diagnosis and treatment of complications, bedside care. The incidence of falciparum malaria and non-falciparum malaria
malaria per 1000 febrile patients was respectively 0.71 and 0.17 (Table 2). More details about cost parameters and epidemiological parameters were shown in Table 1 and 2.

The results of deterministic cost-effectiveness analysis based on the base case value (Table 1, 2) are shown in Table 3. MDT2 (RDT) had the highest number of appropriately diagnosed and treated malaria cases (245 cases) compared with MDT1 (238 cases) and MDT3 (221 cases) but it also had the highest costs (about 4.47 million USD). No strategy was dominated.

For one-way sensitivity analysis of cost parameters, the CEA result was robust to most of parameters in the range (Table 1), except the labor cost of laboratory staff, and other medical costs for false-positive cases. Table 6 showed that ICER was sensitive to varying labor cost of laboratory staff. When the labor cost (per hour) was USD 3.52, MDT3 was dominated. However, when the labor cost increased to USD 10.17 per hour, MDT1 was dominated. When labor cost fluctuated around USD 6.80, such as USD 5.18, 6.84, or 8.50, the results of sensitivity analysis were similar to the base-case results. No strategy was dominated. Figure 2 showed that when other medical costs for one FP case were lower than USD 506, MDT1 was dominated. ICER in MDT2 was found to be more sensitive to the changes in the other medical costs of one FP case.

For one-way sensitivity analysis of cost epidemiological parameters in Table 2, the deterministic CEA results was robust to the sensitivity and specificity of RDT, but can be influenced by the sensitivity and specificity of microscopy. If the sensitivity of microscopy was above 92.58%, the MDT1 would have the highest effect, and MDT2 would be dominated by MDT1. If the specificity of microscopy was below 99.1%, the MDT1 would be dominated by MDT2.

For two-way sensitivity of the proportion of falciparum malaria and non-falciparum malaria, while the annual incidence of malaria was low and stable (Table 4), the CEA result was not sensitive to the change in the proportion of falciparum. Although ICERs decreased when the proportion of falciparum increased (Figure 3).

For probabilistic sensitivity analysis, based on the distributions of key parameters (Table 5), the incremental cost-effectiveness (ICE) plane was made to show the result of 1000 Monte Carlo simulations for MDT1 versus MDT3 and MDT2 versus MDT3 (Figure 4). The majority of simulations for MDT1 compared with MDT3 were in the northeast quadrant, indicating that MDT1 resulted in higher effect at an increasing cost. And the simulations for MDT2 compared with MDT3 were in the same quadrant, indicating that MDT2 also resulted in higher effect at an increasing cost. But the distributions of two series of scatter points overlapped in Figure 4. So Figure 5 was made to show the ICE plan for simulations for MDT2 versus MDT1. In Figure 5, there were 61.2% scatter points in northeast quadrant, 26.3% in southeast, 20.0% in southwest, and 10.5% in northwest, indicating that MDT2 resulted in higher effect at an increasing cost with a high probability (61.2%).

Discussion
The CEA results suggested that MDT2 (RTD) has more effect than MDT1 (microscopy) and MDT3 (RTD followed by microscopy) with the higher cost in elimination setting. The part of result, that RTD had more effect than microscopy, was in line with two similar researches in Afghanistan and Uganda [15, 29]. But they indicated that RTD had lower cost than microscopy. There was still a difference between this research and theirs. It was that they did not calculated the cost of treating FP and FN cases into the total cost. But in this research, the total costs for each strategy consisted of the diagnosis cost and the treatment cost of FP and FN cases. In area without local transmission or very low transmission, the small gap in specificity between microscopy and RTD would be amplified by the large number of non-patients. Our results indicated that the other medical costs (excluding the malaria diagnosis and treatment) of FP cases was the main cost for the higher total cost of MDT2 when it was compared to either MDT1 or MDT3. Although the diagnosis cost per febrile patient in MDT2 was lower than the other two strategies. There were more FP cases in MDT2 because of its slightly lower specificity, which causes the more unnecessary treatment costs and higher total cost. Now in Jiangsu, many hospitals tended to treat malaria case as inpatient. From the doctor's perspective, hospitalization meant better compliance, and lower retransmission risks. From the patient's perspective, hospitalization meant that part of medical expenses could be reimbursed by insurance. So this tendency was the common intention of both doctors and patients, and it actually made MDT2 more costly than other strategies due to more FP treated as inpatient.

Since the results also indicated that the total costs of MDT2 was sensitive to the other medical costs of FP cases, it was suggested that MDT2 could be a more cost-effective strategy if the number and costs of FP cases could be controlled. There were many measures that could be taken, such as re-testing by other more accurate diagnostic technologies, restricting its use in febrile patients without travel history in endemic areas, and reducing the hospitalization of mild patients. Therefore, this study suggested setting standards for hospitalization of malaria case would control the total cost of RTD strategy.

If all the patients with RTD positive results could be retested by microscopy immediately, like MDT3, most FP cases could be avoided. However, meanwhile, some patients with malaria would be missed diagnosis due to low sensitivity of microscopy. Compared with local center for disease control and prevention (CDC), the maintenance of microscopy capability to detect malaria in medical institutions is more difficult and the cost of training was higher. So we suggested that all blood samples of patients with positive RTD in hospitals should be redetected by microscopy or molecular detection techniques, such as polymerase chain reaction (PCR) or loop-mediated isothermal amplification (LAMP), in CDC. The county-level CDC In China was responsible for microscopic review of malaria cases reported by medical institutions. PCR or LAMP were used by CDC to improve the sensitivity and identify the species of *Plasmodium*. This was also a part of content of the 1-3-7 malaria surveillance and response strategy in China [30]. If we could detect FP cases timely in this way, and terminate wrong treatment, RTD would be more cost-effective, and even dominate microscopy, when other medical costs of FP case are under 506 USD based on our results (Figure 2).
The sensitivity of microscopy depended on the skill level and proficiency of laboratory personnel. In areas without local transmission, doctors may encounter few imported malaria cases. It was challenging to maintain the malaria diagnosis skills in China's primary health care, such as Township Health Centers (THCs) and Community Health Centers (CHCs). This was a common situation for most countries in malaria elimination or malaria-free phase. Continuous training was necessary to maintain the skill level of laboratory personnel. Even so, in most THCs, CHCs or hospitals in elimination setting, the high sensitivity of the microscopy was still difficult to maintain [31-33]. Therefore, the sensitivity and specificity of the microscopy were less likely to reach the thresholds which can make microscopy dominant to RDT. Moreover, with the economic development, laboratory personnel salary in general hospitals in Central city was close to the upper limit of the range adopted in the sensitivity analysis. The results of one-way sensitivity analysis also indicated that RDT would dominate microscopy in other specific scenarios, such as, when the proficiency of laboratory personnel decreased, and salary increased. Than the image recognition based on artificial intelligence is likely to reduce labor costs and maintain the accuracy of microscopy [34, 35]. But for now, it was difficult to for microscopy to have a higher sensitivity compared to RDT. Considering the potential local transmission risk caused by FN cases, we suggested that RDT should be the first choice in the area targeting for elimination.

There were huge differences in the proportion of *Plasmodium* species among CEA researches [12, 15, 16]. In elimination setting, the epidemiological characteristics of imported malaria case was not impacted by the local climate or the area where anopheles were active, but impacted by the areas where imported malaria cases came from. In China, the main factor that has impact on imported cases was the return of migrant workers. The proportion of *falciparum* in all malaria cases was constantly changing each year. Therefore, sensitivity analysis was performed to evaluate the robustness of CEA results to this kind of changes in the proportion of *falciparum*. The result indicated that MDT2 (RDT) always had more effect than other strategies, when the proportion of *falciparum* varied between 50% and 100%.

This research offered evidence with a realistic vision for the area in the elimination setting, where the resources still need to be continuously invested in order to achieve and maintain malaria-free. The evidence would inform decision makers that an effective sustainable surveillance system could help to avoid the cost of treating FP cases, and then make RDT more cost-effective.

This study had the limitation in the collection of medical cost data. The best plan was to connect to all of the hospitals that treated malaria cases in 2018, and extract medical cost information from their HIS. However, due to resource limit and time constraints, we couldn’t receive consent from all of the hospitals. For ameliorating the potential impact of this limitation on the results, we assigned the credible range, that was calculated by standard statistical methods, to each cost parameter in PSA.

**Conclusions**

The cost-effectiveness analysis suggested that MDT2 (RDT) strategy has the higher effects and higher total cost compared with MDT1 (microscopy) and MDT3 (RDT followed by microscopy) in the setting of
malaria elimination. These results were robust to the majority of cost parameters in sensitivity analysis, except labor costs and treatment costs for FP case. RDT would be the dominant strategy if the treatment costs of FP cases could be controlled or when labor costs were higher than USD 10.17 per hour.

**Abbreviations**

ACTs: Artemisinin-based combination therapies;

CDC: Center for disease control and prevention;

CEA: Cost-effectiveness analysis;

CER: Cost-effectiveness ratio;

CHCs: Community Health Centers;

CNY: Chinese Yuan;

FN: False-negative;

FP: False-positive;

HIS: Hospital information system;

ICER: Incremental cost-effectiveness ratio;

ICE: Incremental cost-effectiveness;

LAMP: Loopmediated isothermal amplification;

MDT: Malaria diagnostic testing;

PCR: Polymerase chain reaction;

PSA: Probabilistic Sensitivity Analysis;

RDT: Rapid diagnostic test;

THCs: Township Health Centers;

TN: True-negatives;

TP: True-positives;

USD: United States Dollar;

WHO: World Health Organization.
Declarations

Ethics approval and consent to participate

This was a modeling study, thus it did not involve any experiments in humans. The study was approved by the Institutional Review Board (IRB00004221) of Jiangsu Institute of Parasitic Diseases, Wuxi, China. And all data was anonymized.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

All authors declare that they have no competing interests.

Funding

This study was supported by National Key R&D Program of China (No. 2019YFC1200805), the Jiangsu Provincial Department of Science and Technology (BE2018020), and the Jiangsu Provincial Project of Invigorating Health Care through Science, Technology and Education. The funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.

Authors’ contributions

YD, JC, and JH conceived and designed the study. YD, XL, JJ, HZ, SZ, and GZ were responsible for data collection. YD performed the economic analysis and was responsible for the first draft of the manuscript while JH, JC, and WW critically revised the manuscript. All authors read and approved the final manuscript.

Acknowledgment

We are grateful for the close support of experts of Jiangsu Institute of Parasitic Diseases. The authors also thank Wendy Babidge and Di Liang for their assistance in writing.

References

1. WHO. World malaria report 2019: World Health Organization; 2019. https://www.who.int/malaria/publications/world-malaria-report-2019/en/. Accessed 12 Nov 2019
2. WHO. World malaria report 2018: World Health Organization; 2018. https://www.who.int/malaria/publications/world-malaria-report-2018/report/en/. Accessed 12 Nov 2019

3. Zhang L, Feng J, Tu H, Xia Z, Zhou S. The challenge for malaria elimination: the epidemiological characteristics of Plasmodium vivax in China from 2011 to 2018. Chin J Parasitol Parasit Dis. 2019;37(5):1-7. (in Chinese)

4. Feng J, Zhang L, Huang F, Yin JH, Tu H, Xia ZG, Zhou SS, Xiao N, Zhou XN. Ready for malaria elimination: zero indigenous case reported in the People's Republic of China. Malar J. 2018;17(1):315.

5. WHO. Global technical strategy for malaria 2016-2030: World Health Organization; 2015. https://www.who.int/malaria/publications/atoz/9789241564991/en/. Accessed 20 May 2019

6. Mukkala AN, Kwan J, Lau R, Harris D, Kain D, Boggild AK. An Update on Malaria Rapid Diagnostic Tests. Curr Infect Dis Rep. 2018; doi: 10.1007/s11908-018-0655-4.

7. Ranadive N, Kunene S, Darteh S, Ntshalintshali N, Nhlabathi N, Dlamini N, Chitundu S, Saini M, Murphy M, Soble A et al. Limitations of Rapid Diagnostic Testing in Patients with Suspected Malaria: A Diagnostic Accuracy Evaluation from Swaziland, a Low-Endemicity Country Aiming for Malaria Elimination. Clin Infect Dis. 2017;64(9):1221-1227.

8. Rossi G, De Smet M, Khim N, Kindermans J, Menard D. Performance of Rapid Diagnostic Testing in Patients with Suspected Malaria in Cambodia, a Low-Endemicity Country Aiming for Malaria Elimination. Clin Infect Dis. 2017;65(10):1769-1770.

9. Zhu W, Ling X, Shang W, Du Y, Liu J, Cao Y, Yang M, Zhu G, Cao J, Huang J. High value of rapid diagnostic tests to diagnose malaria within children: A systematic review and meta-analysis. J Glob Health. 2020; doi: 10.7189/jogh.10.010411.

10. Ling X, Jin J, Zhu G, Wang W, Cao Y, Yang M, Zhou H, Cao J, Huang J. Cost-effectiveness analysis of malaria rapid diagnostic tests: a systematic review. Infect Dis Poverty. 2019; doi: 10.1186/S40249-019-0615-8.

11. Chanda P, Castillo-Riquelme M, Masiye F. Cost-effectiveness analysis of the available strategies for diagnosing malaria in outpatient clinics in Zambia. Cost Eff Resour Alloc. 2009;7:5.

12. de Oliveira MR, Giozza SP, Peixoto HM, Romero GA. Cost-effectiveness of diagnostic for malaria in Extra-Amazon Region, Brazil. Malar J. 2012;11:390.

13. Escribano FB, Hansen KS, Gyapong M, Bruce J, Narh BS, Narh CT, Allotey NK, Glover R, Azantilow NC, Bart-Plange C et al. Cost-effectiveness analysis of the national implementation of integrated community case management and community-based health planning and services in Ghana for the treatment of malaria, diarrhoea and pneumonia. Malar J. 2017;16(1):277.

14. Hansen KS, Ndyomugyenyi R, Magnusen P, Lal S, Clarke SE. Cost-effectiveness analysis of malaria rapid diagnostic tests for appropriate treatment of malaria at the community level in Uganda. Health Policy Plan. 2017;32(5):676-689.
15. Hansen KS, Grieve E, Mikhail A, Mayan I, Mohammed N, Anwar M, Baktash SH, Drake TL, Whitty CJ, Rowland MW et al. Cost-effectiveness of malaria diagnosis using rapid diagnostic tests compared to microscopy or clinical symptoms alone in Afghanistan. Malar J. 2015;14:217.

16. Ansah EK, Epokor M, Whitty CJ, Yeung S, Hansen KS. Cost-effectiveness analysis of introducing RDTs for malaria diagnosis as compared to microscopy and presumptive diagnosis in central and peripheral public health facilities in Ghana. Am J Trop Med Hyg. 2013;89(4):724-736.

17. Zhou H, Cao J, Wang W, Li J, Gu Y, Zhu G, Gao Q. Epidemic and control of malaria in Jiangsu Province. Chin J Schisto Control. 2009;21(6):503-506. (in Chinese)

18. Zhou H, Wang W, Zhu G, Cao Y, Gu Y, Xu S, Zhang C, Lu F, Cao J. Epidemiological analysis of malaria prevalence in Jiangsu Province in 2016. Chin J Schisto Control. 2018;30(1):32-36. (in Chinese)

19. Cao Y, Wang W, Liu Y, Cotter C, Zhou H, Zhu G, Tang J, Tang F, Lu F, Xu S et al. The increasing importance of Plasmodium ovale and Plasmodium malariae in a malaria elimination setting: an observational study of imported cases in Jiangsu Province, China, 2011-2014. Malar J. 2016;15:495.

20. Cao J, Liu Y, Cao Y, Zhu G, Zhou S. Sustained challenge to malaria elimination in China: imported malaria. Chin J Parasitol Parasit Dis. 2018;36(2):93-96. (in Chinese)

21. Zhou Y, Lin Z, Luo C, Li S, Sun X. Meta-analysis of the accuracy of malaria diagnostic tests. J Pathogen Biology. 2017;12(3):242-248, 282. (in Chinese)

22. Li S, Gao L, Zhang Y, Zhou R, Zhao Y. Comprehensive analysis of three detection methods on the laboratory diagnosis of malaria. Henan J Prev Med. 2018;29(4):252-254, 266. (in Chinese)

23. Zhang X, Su X. Practical evaluation of microscopic examination and colloidal gold method in detection of plasmodium. Henan J Prev Med. 2018;29(2):94-95. (in Chinese)

24. Song G, Song G, Zhang H, Zhang C. Application evaluation of Wondfo malaria RDT colloidal gold method in Jining area. Chin Trop Med. 2018;18(1):28-30, 36. (in Chinese)

25. Jiang L, Wang Z, Zhang Y, Zhu M, Zhang X, Ma X, He Y, Zhu Q, Jiang S, Cai L. Analysis on the application of three methods for malaria diagnosis. Chin J Parasitol Parasit Dis. 2017;35(1):53-58. (in Chinese)

26. Edlin R, McCabe C, Hulme C, Hall P, Wright J. Chapter 4: Uncertainty, Probabilistic Analysis and Outputs from Cost Effectiveness Analyses. Cost Effectiveness Modelling for Health Technology Assessment. Switzerland: Springer International Publishing; 2015. p. 59-76.

27. Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model Parameter Estimation and Uncertainty Analysis: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32(5SI):722-732.

28. Limwattananon S. Handling uncertainty of the economic evaluation result: sensitivity analysis. Med Assoc Thai. 2008;91 Suppl 2:59.

29. Batwala V, Magnussen P, Hansen KS, Nuwaha F. Cost-effectiveness of malaria microscopy and rapid diagnostic tests versus presumptive diagnosis: implications for malaria control in Uganda. Malar J. 2011;10:372.
30. Lu G, Liu Y, Beiersmann C, Feng Y, Cao J, Müller O. Challenges in and lessons learned during the implementation of the 1-3-7 malaria surveillance and response strategy in China: a qualitative study. Infect Dis Poverty. 2016;5(1):94.

31. Ding G, Zhu G, Cao C, Miao P, Cao Y, Wang W, Gu Y, Xu S, Wang S, Zhou H et al. The challenge of maintaining microscopist capacity at basic levels for malaria elimination in Jiangsu Province, China. BMC Public Health. 2018;18(1):489.

32. Gu Y, Zhu G, Zhang C, Xu S, Yang M, Zhou H, Cao J. Quality analysis of malaria microscopic examinations in Jiangsu Province from 2011 to 2017. Chin J Schisto Control. 2018;30(4):369-373. (in Chinese)

33. Zhang S, Feng J, Zhang L, Ren X, Geoffroy E, Manguin S, Frutos R, Zhou S. Imported malaria cases in former endemic and non-malaria endemic areas in China: are there differences in case profile and time to response? Infect Dis Poverty. 2019;8(1):61.

34. Pollak JJ, Houri-Yafin A, Salpeter SJ. Computer Vision Malaria Diagnostic Systems-Progress and Prospects. Front Public Health. 2017; doi: doi: 10.3389/fpubh.2017.00219.

35. Torres K, Bachman CM, Delahunt CB, Baldeon JA, Alava F, Vilela DG, Proux S, Mehanian C, McGuire SK, Thompson CM et al. Automated microscopy for routine malaria diagnosis: a field comparison on Giemsa-stained blood films in Peru. Malar J. 2018;17:399.

**Tables**

**Table 1 Cost components and unit costs**
| Items                                                                 | Base case value (USD) | Range for one-way sensitivity analysis |
|----------------------------------------------------------------------|-----------------------|----------------------------------------|
| **Direct medical cost**                                              |                       |                                        |
| 1) Malaria diagnosis                                                 |                       |                                        |
| RDT - Malaria Pf/Pan Whole Blood Test per test                       | 1.51<sup>a</sup>      | 1.21–2.27                              |
| Microscopy - Material cost of thick smear per exam                   | 0.18<sup>a</sup>      | 0.15–0.30                              |
| Labor cost of laboratory staff per hour                              | 6.80<sup>a</sup>      | 3.02–11.33                             |
| Time spent on RDT per test                                          | 0.1 (hour)<sup>a</sup> | 0.08–0.25                              |
| Time spent on thick smear test per test                              | 1 (hour)<sup>a</sup>   | 0.5–1.5                                |
| 2) Malaria treatment                                                 |                       |                                        |
| Chloroquine and primaquine per course of treatment                  | 6.04<sup>a</sup>      | 6.04–7.56                              |
| Dihydroartemisinic and piperaquine per course of treatment          | 4.53<sup>a</sup>      | 4.53–6.80                              |
| Artesunate injection per course of treatment                        | 132.98<sup>a</sup>    | 132.95–151.12                          |
| 3) Other relative diagnosis and treatment                           |                       |                                        |
| Other medical costs for outpatient per uncomplicated malaria case    | 31.58<sup>b</sup>     | 30.22–45.34                            |
| Other medical costs for inpatient per uncomplicated malaria case     | 1167.83<sup>c</sup>   | 824.49–1511.17                         |
| Other medical costs per severe malaria case                         | 17 569.29<sup>c</sup> | 10 578.17–45,335.03                    |
| Other medical costs per false positive case                         | 786.34<sup>c</sup>    | 435.35–1137.33                         |
| Other medical costs per false negative case                         | 11 652.67<sup>c</sup> | 7555.84–22 667.51                      |
| **Direct non-medical cost**                                          |                       |                                        |
| Travel cost of patient visiting health care sector per person        | 3.02<sup>b</sup>      | 1.51–4.53                              |

a: Data collected by key informant interview; b: Data collected by patient survey; c: Data collected from hospital information system.

RDT: Rapid diagnostic test; USD: United States Dollar

Table 2 Epidemiological parameters considered in the analytic model
| Parameter                                                                 | Base case value | Range for one-way sensitivity analysis |
|--------------------------------------------------------------------------|----------------|----------------------------------------|
| *falciparum* cases per 1000 febrile patients                             | 0.7073<sup>a</sup> | 0.3537–1.0610                          |
| Non-*falciparum* cases per 1000 febrile patients                        | 0.1746<sup>a</sup> | 0.0873–0.2619                          |
| Probability of conversion of *falciparum* malaria into severe case      | 3%<sup>b</sup>   | 1%–5%                                  |
| Probability of conversion of non-*falciparum* malaria into severe case  | 0.10%<sup>b</sup> | 0.05%–0.5%                             |
| Proportion of inpatient in all uncomplicated malaria cases               | 66%<sup>b</sup>  | 20%–80%                                |
| Sensitivity of RDT for *falciparum* malaria                             | 93%<sup>[21–25]</sup> | 91%–93%                               |
| Sensitivity of RDT for non-*falciparum* malaria                         | 91%<sup>[21–25]</sup> | 89%–92%                               |
| Specificity of RDT                                                      | 99%<sup>[21–25]</sup> | 98%–99%                               |
| Sensitivity of microscopy                                                | 90%<sup>c</sup>  | 85%–95%                                |
| Specificity of microscopy                                                | 100%<sup>c</sup> | 90%–100%                               |

<sup>a</sup>: Data collected from malaria surveillance reports; <sup>b</sup>: Data collected by patient survey; <sup>c</sup>: Data collected by key informant interview.

RDT: Rapid diagnostic test

**Table 3 The results of cost-effectiveness analysis**

| Strategy | MDT3          | MDT1          | MDT2          |
|----------|---------------|---------------|---------------|
|          | RDT and Microscopy | Microscopy | RDT | Microscopy |
| Cost (USD) | 2 754 254.53 | 3 626 228.08 | 4 465 725.40 |
| Effect (case) | 220.5 | 238.11 | 245 |
| Cost/Effect | 12 491.08 | 15 229.33 | 18 227.64 |
| Incremental cost | - | 871 973.55 | 1 711 471.87 |
| Incremental effect | - | 17.61 | 24.5 |
| ICER | - | 49 514.29 | 69 856.70 |
Note: MDT: Malaria diagnostic testing; RDT: Rapid diagnostic tests; USD: United States Dollar; ICER: Incremental cost-effectiveness ratio.

**Table 4 Value set of incidence in sensitivity analysis for the proportion of falciparum malaria**

| The proportion of *falciparum* malaria simulated in model | 50% | 60% | 70% | 80% | 90% | 100% |
|----------------------------------------------------------|-----|-----|-----|-----|-----|------|
| The incidence of *falciparum* malaria (per 1000 febrile patients) | 0.441 | 0.529 | 0.617 | 0.706 | 0.794 | 0.882 |
| The incidence of Non-*falciparum* malaria (per 1000 febrile patients) | 0.441 | 0.353 | 0.265 | 0.176 | 0.088 | 0 |

**Table 5 Parameters and distributions for Monte Carlo simulation**
| Parameters                                                                 | Distribution | PSA parameters in Treeage |
|---------------------------------------------------------------------------|--------------|---------------------------|
| RDT - Malaria Pf/Pan Whole Blood Test per test                            | Uniform      | Low = 1.21, High = 1.51   |
| Travel cost of patient visiting health care sector per person             | Triangular   | Min = 0.30, Likieliest = 3.02, Max = 6.35 |
| Labor cost of laboratory staff per hour                                   | Uniform      | Low = 6.80, High = 7.56   |
| Other medical costs for outpatient per uncomplicated malaria case         | Gamma        | Mean = 31.58, SD = 88.4   |
| Other medical costs for inpatient per uncomplicated malaria case          | Gamma        | Mean = 1167.83, SD = 604.00 |
| Sensitivity of RDT for *Plasmodium falciparum*                            | Beta         | Mean = 0.93, SD = 0.02    |
| Sensitivity of RDT for non-*Plasmodium falciparum*                        | Beta         | Mean = 0.91, SD = 0.03    |
| Specificity of RDT                                                        | Beta         | Mean = 0.99, SD = 0.005   |
| Sensitivity of microscopy                                                 | Triangular   | Min = 0.85, Likieliest = 0.90, Max = 0.95 |
| Specificity of microscopy                                                 | Triangular   | Min = 0.99, Likieliest = 1.00, Max = 1.00 |
| Time spent on RDT per test                                                | Triangular   | Min = 0.08, Likieliest = 0.1, Max = 0.25 |
| Time spent on thick smear test per test                                   | Triangular   | Min = 0.50, Likieliest = 1.00, Max = 1.50 |

PSA: Probabilistic sensitivity analysis; RDT: Rapid diagnostic tests; SD: Standard deviation.

**Table 6 One-way sensitivity analysis of labor cost of laboratory staff**
| Labor Cost (USD, per hour) | Strategy | Cost (USD, million) | Effect (case) | C/E  | Increment Cost | Increment Effect | ICER    |
|---------------------------|----------|---------------------|--------------|------|----------------|-----------------|---------|
| 3.52                      | MDT1     | 2.642               | 238          | 0.011| -              | -               | -       |
|                           | MDT3*    | 2.645               | 220          | 0.012| 0.003          | -18             | -0.0002*|
|                           | MDT2     | 4.367               | 245          | 0.018| 1.726          | 7               | 0.2505  |
| 5.18                      | MDT3     | 2.7                 | 220          | 0.012| -              | -               | -       |
|                           | MDT1     | 3.14                | 238          | 0.013| 0.44           | 18              | 0.025   |
|                           | MDT2     | 4.417               | 245          | 0.018| 1.277          | 7               | 0.1853  |
| 6.84                      | MDT3     | 2.756               | 220          | 0.012| -              | -               | -       |
|                           | MDT1     | 3.639               | 238          | 0.015| 0.883          | 18              | 0.0502  |
|                           | MDT2     | 4.467               | 245          | 0.018| 0.828          | 7               | 0.1202  |
| 8.5                       | MDT3     | 2.811               | 220          | 0.013| -              | -               | -       |
|                           | MDT1     | 4.138               | 238          | 0.017| 1.327          | 18              | 0.0753  |
|                           | MDT2     | 4.517               | 245          | 0.018| 0.379          | 7               | 0.0551  |
| 10.17                     | MDT3     | 2.866               | 220          | 0.013| -              | -               | -       |
|                           | MDT2     | 4.567               | 245          | 0.019| 1.701          | 24              | 0.0694  |
|                           | MDT1*    | 4.636               | 238          | 0.019| 0.069          | -7              | -0.0101*|

Note: *: The strategy that was dominated by others.

USD: United States Dollar; C/E: Cost/effect; ICER: Incremental cost-effectiveness ratio; MDT: Malaria diagnostic testing.

**Figures**
**Figure 1**

Basic structure of decision tree. +: Positive; -: Negative; FN: False-negative; FP: False-positive; TN: True-negatives; TP: True-positives.
Figure 2

Sensitivity analysis of other medical costs – one false-positive case (USD).

Fig. 2 Sensitivity analysis of other medical costs – one false-positive case (USD)
Figure 3

Sensitivity analysis of the proportion of falciparum. MDT: Malaria diagnostic testing; RDT: Rapid diagnostic test.
Figure 4

Incremental cost-effectiveness plan for Monte Carlo simulations for MDT1 versus MDT3 and MDT2 versus MDT3. MDT: Malaria diagnostic testing.
Fig. 5 Incremental cost-effectiveness plan for Monte Carlo simulations for MDT2 versus MDT1.

Figure 5

Incremental cost-effectiveness plan for Monte Carlo simulations for MDT2 versus MDT1. MDT: Malaria diagnostic testing.